Arwen Podesta, MD, defines what prescription digital therapeutics (PDTs) are, describes how they differ from nonprescription digital health tools, and details the FDA review process for PDTs.
Can you define what prescription digital therapeutics (PDTs) are and describe how they differ from nonprescription digital health tools?
What is the FDA review process for PDTs, and how is it different from the review process for prescription drugs and medical devices? How does FDA authorization of a PDT factor into clinical decision-making about a treatment?
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
Arwen Podesta, M.D., discussed prescription digital therapeutics for people with mental health and substance abuse conditions in a Managed Healthcare Executive K-Cast video series. Podesta is a New Orleans-based board-certified adult psychiatrist with subspecializations in addiction medicine, forensic psychiatry and integrative medicine.
Read More